African Programme for Onchocerciasis Control 1995–2015: Updated Health Impact Estimates Based on New Disability Weights

Luc E. Coffeng1*, Wilma A. Stolk1, Horwarat G. M. Zoure2, J. Lennert Veerman1,3, Koffi B. Agblewonu2, Michele E. Murdoch4, Mounkaila Noma3, Grace Fobi3, Jan Hendrik Richardus1, Donald A. P. Bundy5, Dick Habbema1, Sake J. de Vlas1, Uche V. Amazigo6

1 Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, 2 African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso, 3 School of Population Health, The University of Queensland, Herston, Australia, 4 Department of Dermatology, Watford General Hospital, Watford, United Kingdom, 5 Human Development Network, The World Bank, Washington, D.C., United States of America, 6 Independent Consultant, Enugu, Nigeria

* E-mail: l.coffeng@erasmusmc.nl

**Funding:** This study was funded by the World Health Organization/African Programme for Onchocerciasis Control 1995–2015. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

Since 1995, the African Programme for Onchocerciasis Control (APOC) has coordinated mass treatment with ivermectin in 16 sub-Saharan countries (Angola, Burundi, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Libya, Malawi, Nigeria, North Sudan, South Sudan, Uganda, and the United Republic of Tanzania) with the aim to control morbidity due to infection with Onchocerca volvulus, a filarial nematode. Recently, we predicted trends in prevalence of infection, visual impairment, blindness, and troublesome itch due to onchocerciasis in APOC countries for the period 1995–2015, based on extensive data on pre-control infection levels, population coverage of ivermectin mass treatment, and the association between infection and morbidity [1]. We also estimated the associated health impact, expressed in disability-adjusted life years (DALYs). However, the estimated health impact was based on disability weights from the 2004 update of the Global Burden of Disease (GBD) study [2], which have been criticized for being based solely on the opinions of health professionals [3,4]. The recently published GBD 2010 study addressed this criticism by providing updated disability weights based on household surveys in Bangladesh, Indonesia, Peru, and Tanzania, an open internet survey, and a telephone survey in the United States [5]. As a result of this population-based approach, the disability weights for visual impairment, blindness, and troublesome itch have changed considerably and should better reflect our ideas and beliefs as a society of what constitutes health. For future reference, we provide an updated estimate of the health impact of APOC activities, based on previously predicted trends in averted number of cases with infection and morbidity, but using updated disability weights for visual impairment, blindness, and troublesome itch.

Identical to previously used methods [1], we calculated the health impact of APOC for each year between 1995 and 2015, expressed in DALYs averted. The DALY metric is the sum of years of life lost (YLL) due to premature mortality (from blindness) and years lived in disability (YLD), weighted by disability weights representing the loss of quality of life [5]. DALYs averted were calculated as the difference between two scenarios: a factual scenario in which APOC activities have been taken place as documented, and a counterfactual scenario in which APOC activities have not taken place at all, effectively translating to $D\text{ALY}_{\text{averred}} = \Delta YLD_{\text{blindness}} + \Delta YLD_{\text{visual impairment}} + \Delta YLD_{\text{itch}}$.

Here, $\Delta YLD_{\text{blindness}}$ is the averted number of YLL related to premature mortality from blindness (as previously estimated [1]), and $\Delta YLD_{\text{x}}$ is the averted number of YLD due to symptom x. Averted YLD were calculated as $\Delta YLD_{\text{x}} = \Delta N_x \cdot d_w z$, where $\Delta N_x$ is the averted number of person-years of symptom x (i.e., difference in annually prevalent cases between the factual and counterfactual scenarios, as previously estimated [1]), and $d_w z$ is the associated updated disability weight, derived from the GBD 2010 study [5].

Compared to previous disability weights [2], updated weights were considerably lower for visual impairment (0.033, previously 0.282) and blindness (0.193, previously 0.594), reflecting that the loss in quality of life because of these manifestations is considerably lower than previously assumed. On the contrary, the disability weight for troublesome itch has increased (0.108, previously 0.068). The disability weight for visual impairment represents “moderate visual impairment” in the GBD 2010 study. The updated disability weights do not include a category for itch alone. Hence the disability weight for troublesome itch was derived from a...
generic class of disability weights for "disfigurement with itch or pain." This class consists of three severity levels, characterized as "causing some worry and discomfort" (disability weight 0.029), "a person having trouble concentrating and sleeping" (disability weight 0.187), and "causing a person to avoid social contact, feel worried, sleep poorly, and think about suicide" (disability weight 0.562). Based on original precontrol data from a previously published, multicountry study [6] (excluding data from Ghana and Cameroon, which were collected based on convenience sampling rather than household surveys), we assumed that onchocercal itch regularly causes insomnia in about half of the cases and, therefore, calculated YLD due to itch using the mean of the disability weights for the first two severity levels (0.108). We assumed that this disability weight also applies during ivermectin mass treatment, even though the fraction of insomniacs among cases of itch might decrease with repeated mass treatments (due to lower infection loads and consequent lower severity of itch). Unfortunately, previous studies on trends of onchocercal itch during ivermectin mass treatment do not report on insomnia [7,8]. Therefore, if anything, we may be underestimating the impact of ivermectin mass treatment on the burden of itch (and the associated DALYs averted).

Figure 1 illustrates trends in DALYs lost due to troublesome itch, visual impairment, and blindness, and DALYs averted by APOC. Table 1 gives more detailed information on the number of prevalent cases (according to the factual scenario) and DALYs lost and averted per year. For onchocercal visual impairment and blindness, the updated estimates of the averted burden turned out lower than the previous estimates. In contrast, for troublesome itch, the updated estimate of the burden averted turned out higher than the previous estimate. For visual impairment and troublesome itch, the difference between previous and updated estimates was proportional to the change in values of the associated disability weights. For blindness, however, this difference was not proportional, as the burden of blindness also included years of life lost due to premature mortality (which is exactly the same for previous and updated estimates).

Overall, we estimated that APOC has cumulatively averted 8.9 million DALYs due to onchocerciasis through 2010, and will avert another 10.1 million DALYs between 2011 and 2015, adding up to a total of 19.0 million DALYs averted through 2015. These updated estimates do not differ much from previous estimates (8.2 million DALYs averted through 2010, and another 9.2 million between 2011 and 2025). In relative terms, the burden of onchocerciasis in APOC areas has decreased from 23.1 DALYs per 1,000 persons in 1995 to 8.6 DALYs per 1,000 persons in 2010, and is expected to further decrease to 3.7 DALYs per 1,000 persons in 2015.

The updated disability weights provided by the GBD 2010 study are based on population surveys rather than expert opinion. Therefore, they are presumably less subjective and should better reflect our ideas and beliefs as a society of what constitutes health than previous disability weights [3]. However, it has been argued that the disability weights for visual impair-
Table 1. Population at risk, number of cases, and disability-adjusted life years lost and averted due to onchocerciasis in areas covered by APOC.

| Year | Population (At risk of infection) | Infected | Troublesome itch | Visual impairment | Blindness | Disability-adjusted life years lost (thousands) | Disability-adjusted life years averted (thousands) |
|------|-----------------------------------|----------|-----------------|------------------|----------|-----------------------------------------------|-----------------------------------------------|
| 1995 | 71,474                            | 32,330   | 10,202          | 889              | 404      | 1,102                                        | 29                                            |
| 1996 | 73,310                            | 33,209   | 10,499          | 910              | 410      | 1,134                                        | 30                                            |
| 1997 | 75,195                            | 34,073   | 10,780          | 931              | 418      | 1,164                                        | 31                                            |
| 1998 | 77,132                            | 34,951   | 10,925          | 957              | 427      | 1,180                                        | 32                                            |
| 1999 | 79,122                            | 35,816   | 10,692          | 974              | 430      | 1,155                                        | 32                                            |
| 2000 | 81,165                            | 36,522   | 10,749          | 981              | 427      | 1,161                                        | 32                                            |
| 2001 | 83,144                            | 36,998   | 10,653          | 987              | 420      | 1,151                                        | 33                                            |
| 2002 | 85,172                            | 37,338   | 10,456          | 995              | 410      | 1,129                                        | 33                                            |
| 2003 | 87,249                            | 37,502   | 10,073          | 990              | 402      | 1,088                                        | 33                                            |
| 2004 | 89,377                            | 37,458   | 9,705           | 977              | 391      | 1,048                                        | 32                                            |
| 2005 | 91,558                            | 37,196   | 9,357           | 965              | 379      | 1,011                                        | 32                                            |
| 2006 | 93,928                            | 36,779   | 8,684           | 951              | 369      | 938                                          | 31                                            |
| 2007 | 96,360                            | 36,093   | 8,111           | 931              | 358      | 876                                          | 31                                            |
| 2008 | 98,857                            | 35,085   | 7,539           | 910              | 345      | 814                                          | 30                                            |
| 2009 | 101,419                           | 33,811   | 6,564           | 885              | 330      | 709                                          | 29                                            |
| 2010 | 104,050                           | 32,246   | 5,836           | 854              | 310      | 630                                          | 28                                            |
| 2011 | 106,750                           | 30,355   | 5,157           | 825              | 290      | 557                                          | 27                                            |
| 2012 | 109,521                           | 28,244   | 4,417           | 797              | 271      | 477                                          | 26                                            |
| 2013 | 112,366                           | 25,979   | 3,724           | 762              | 254      | 402                                          | 25                                            |
| 2014 | 115,287                           | 23,591   | 3,074           | 724              | 237      | 332                                          | 24                                            |
| 2015 | 118,285                           | 21,115   | 2,478           | 690              | 220      | 268                                          | 23                                            |
| Subtotal 1995–2010 | | | | | | | | |
| Total 1995–2015 | | | | | | | | |

*Infection defined as presence of at least one adult female worm.

doi:10.1371/journal.pntd.0002759.t001
ment and blindness underestimate the burden of vision loss in rural Africa [9,10]. One of the main arguments is that the surveys used to establish new disability weights did not adequately cover rural Africa (Tanzania only). Furthermore, being strictly a metric of health loss rather than wellbeing [5], DALYs do not capture the effects of vision loss and skin disease on socioeconomic status [11] and productivity [12,13]. Therefore, the impact of APOC most likely encompasses more than what we report here in terms of health impact.

According to our updated estimates, skin disease is now the most important contributor to the burden of onchocerciasis, rather than eye disease. Moreover, the true disease burden of onchocercal skin disease (and the burden averted by APOC) is still larger than we estimate here, as our updated estimates do not include disfiguring skin disease, or other sequelae potentially associated with onchocerciasis, such as epilepsy [14] and head-nodding syndrome [15]. The additional burden of disfiguring skin disease is probably considerable, given the relatively high values of the updated disability weights for disfiguring skin disease and the high precontrol prevalence of disfiguring skin disease in areas endemic for onchocerciasis [6]. This underlines the importance of onchocercal skin disease, especially in forest areas where vision loss is relatively rare [16].

Acknowledgments

We thank Drs. M. C. Asuzu, M. Hagan, W. H. Makunde, P. Ngoumou (deceased), K. F. Oghuagu, D. Okello, G. Ozoh, and J. H. F. Remme for their contributions to precontrol data on nodule prevalence and prevalence of itch.

References

1. Coffeng LE, Stolk WA, Zoure’ HGM, Veerman JL, Aghbelouso KF, et al. (2013) African Programme For Onchocerciasis Control 1995–2015: model-estimated health impact and cost. PLoS Negl Trop Dis 7: e2032.
2. World Health Organization (2008) The Global Burden of Disease: 2004 Update. World Health Organization.Available: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/. Accessed 8 May 2014.
3. Mont D (2007) Measuring health and disability. Lancet 369: 1658–1663.
4. King CH, Bertino A-M (2008) Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Negl Trop Dis 2: e209.
5. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, et al. (2012) Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380: 2129–2143.
6. Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, et al. (2002) Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 96: 283–296.
7. Brieger WR, Aveyeboh AK, Ekeanya CI, Hagan M, Oghuagu KF, et al. (1998) The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health 3: 951–961.
8. Ozoh GA, Murdoch ME, Bissek A-C, Hagan M, Oghuagu K, et al. (2011) The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. Trop Med Int Health 16: 473–483.
9. Taylor HR, Jonas JB, Keeffe J, Leasher J, Naidoo K, et al. (2013) Disability weights for vision disorders in Global Burden of Disease study. Lancet 381: 23.
10. Salomon JA, Vos T, Murray CJL (2013) Disability weights for vision disorders in Global Burden of Disease study—Authors’ reply. Lancet 381: 23–24.
11. Alonso LM, Alvar J (2010) Stigmatizing neglected tropical diseases: a systematic review. Soc Med 5: 218–227.
12. Benton B (1998) Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Ann Trop Med Parasitol 92 Suppl 1: S33–S39.
13. Kim AK, Tandon A, Hailu A (1997) Health and labor productivity: the economic impact of onchocercal skin disease. Policy Research Working Paper 1836. Ethiopia: Onchocerciasis Coordination Unit, Africa Human Development Department, The World Bank and Institute of Pathobiology, University of Addis Ababa.
14. Pion SDS, Kaiser C, Broux-Toni F, Cournoul A, Taylor MM, et al. (2009) Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys. PLoS Negl Trop Dis 3: e461.
15. Williams SCP (2012) Nodding syndrome leaves baffled scientists shaking their heads. Nat Med 18: 334.
16. Murdoch ME (2010) Onchodermatitis. Curr Opin Infect Dis 23: 124–131.